Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ocaratuzumab, an antibody targeting CD20.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lodelcizumab, an antibody targeting PCSK9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lirilumab, an antibody targeting KIRD2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imgatuzumab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dusigitumab, an antibody targeting IGF1 and IGF2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tovetumab, an antibody targeting PDGFRA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Otlertuzumab, an antibody targeting CD37.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lifastuzumab, an antibody targeting SLC34A2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fletikumab, an antibody targeting IL20.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Eldelumab, an antibody targeting CXCL10.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Anetumab, an antibody targeting MSLN.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vanucizumab, an antibody targeting ANGPT2 × VEGF-A.